JOP20210056A1 - مركبات حمض أميني وطرق استخدامها - Google Patents
مركبات حمض أميني وطرق استخدامهاInfo
- Publication number
- JOP20210056A1 JOP20210056A1 JOP/2021/0056A JOP20210056A JOP20210056A1 JO P20210056 A1 JOP20210056 A1 JO P20210056A1 JO P20210056 A JOP20210056 A JO P20210056A JO P20210056 A1 JOP20210056 A1 JO P20210056A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- amino acid
- acid compounds
- compounds
- integrin
- Prior art date
Links
- -1 Amino acid compounds Chemical class 0.000 title 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| PCT/US2019/055252 WO2020076862A1 (en) | 2018-10-08 | 2019-10-08 | Amino acid compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210056A1 true JOP20210056A1 (ar) | 2021-03-24 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0056A JOP20210056A1 (ar) | 2018-10-08 | 2019-10-08 | مركبات حمض أميني وطرق استخدامها |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11180494B2 (enExample) |
| EP (1) | EP3863711A4 (enExample) |
| JP (1) | JP7523450B2 (enExample) |
| KR (1) | KR20210101205A (enExample) |
| CN (1) | CN113195053B (enExample) |
| AU (1) | AU2019358041A1 (enExample) |
| BR (1) | BR112021006620A2 (enExample) |
| CA (1) | CA3115643A1 (enExample) |
| CL (2) | CL2021000863A1 (enExample) |
| CO (1) | CO2021004279A2 (enExample) |
| CR (1) | CR20210224A (enExample) |
| CU (1) | CU24690B1 (enExample) |
| DO (1) | DOP2021000054A (enExample) |
| EA (1) | EA202190967A1 (enExample) |
| EC (1) | ECSP21032717A (enExample) |
| IL (1) | IL282026A (enExample) |
| JO (1) | JOP20210056A1 (enExample) |
| MX (1) | MX2021004015A (enExample) |
| PE (1) | PE20211463A1 (enExample) |
| PH (1) | PH12021550784A1 (enExample) |
| SG (1) | SG11202103283RA (enExample) |
| TW (1) | TW202028179A (enExample) |
| WO (1) | WO2020076862A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2024145245A2 (en) * | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
| GB202301024D0 (en) * | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN122270455A (zh) * | 2023-12-22 | 2026-06-23 | 北京炫景瑞医药科技有限公司 | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20100037600A (ko) | 2007-06-13 | 2010-04-09 | 브리스톨-마이어스 스큅 컴퍼니 | 응고 인자 억제제로서의 디펩티드 유사체 |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| LT3275883T (lt) | 2015-03-25 | 2021-08-25 | Fujifilm Corporation | Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba |
| KR20190026001A (ko) | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| EP3843728B1 (en) | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en not_active Abandoned
- 2019-10-08 JP JP2021544112A patent/JP7523450B2/ja active Active
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en not_active Withdrawn
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en not_active Ceased
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053B/zh active Active
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko not_active Ceased
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
- 2023-12-19 US US18/545,952 patent/US20240270742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115643A1 (en) | 2020-04-16 |
| CO2021004279A2 (es) | 2021-04-30 |
| AU2019358041A1 (en) | 2021-05-20 |
| US11952376B2 (en) | 2024-04-09 |
| US20200109141A1 (en) | 2020-04-09 |
| CL2021000863A1 (es) | 2021-09-10 |
| CN113195053B (zh) | 2024-08-30 |
| PH12021550784A1 (en) | 2021-10-25 |
| US20220144829A1 (en) | 2022-05-12 |
| EP3863711A4 (en) | 2022-07-06 |
| EP3863711A1 (en) | 2021-08-18 |
| CN113195053A (zh) | 2021-07-30 |
| SG11202103283RA (en) | 2021-04-29 |
| DOP2021000054A (es) | 2021-08-31 |
| MX2021004015A (es) | 2021-06-23 |
| IL282026A (en) | 2021-05-31 |
| WO2020076862A1 (en) | 2020-04-16 |
| CL2023001331A1 (es) | 2023-10-20 |
| ECSP21032717A (es) | 2021-06-30 |
| KR20210101205A (ko) | 2021-08-18 |
| CU20210027A7 (es) | 2021-11-04 |
| JP7523450B2 (ja) | 2024-07-26 |
| US20240270742A1 (en) | 2024-08-15 |
| BR112021006620A2 (pt) | 2021-07-06 |
| TW202028179A (zh) | 2020-08-01 |
| EA202190967A1 (ru) | 2021-09-17 |
| JP2022508657A (ja) | 2022-01-19 |
| PE20211463A1 (es) | 2021-08-05 |
| CR20210224A (es) | 2021-06-08 |
| US11180494B2 (en) | 2021-11-23 |
| CU24690B1 (es) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550784A1 (en) | Amino acid compounds and methods of use | |
| ZA202005437B (en) | Amino acid compounds and methods of use | |
| CR20210041A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| MY188820A (en) | Formulation for anti-?4?7 antibody | |
| MX2025007577A (es) | Inhibidores de la integrina alfa-v-beta-8 y sus usos | |
| CR20230553A (es) | Regímenes de dosificación expandidos para inhibidores de integrina | |
| PH12018501575A1 (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| EA201892020A1 (ru) | Индольные производные и их применение в качестве ингибиторов протеинкиназы | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| MX2020001199A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| PH12016501548B1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| GEP20267870B (en) | Tetrahydrothieno pyridine derivatives as ddrs inhibitors | |
| WO2025019626A3 (en) | Proteosome complex inhibitors targeting clpp1p2 protease |